| Serial Number | 90545040 |
| Word Mark | RNAGADE |
| Filing Date | Wednesday, February 24, 2021 |
| Status | 731 - SECOND EXTENSION - GRANTED |
| Status Date | Tuesday, April 9, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, March 14, 2023 |
| Goods and Services | Pharmaceutical preparations and substances, namely, RNA and DNA therapeutics for the treatment of infectious diseases, blood disorders, sepsis, alopecia, and cognitive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of osteoporosis; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of viral infections; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for treating diabetes; pharmaceutical preparations, namely, RNA and DNA therapeutics for use in chemotherapy; pharmaceutical preparations, namely, RNA and DNA therapeutics for cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, antivirals; therapeutic pharmaceuticals, namely, RNA and DNA therapeutics for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; vaccine preparations, namely, RNA and DNA vaccine preparations; vaccines, namely, RNA and DNA vaccines; anti-epileptic pharmaceutical preparations; human vaccine preparations, namely, RNA and DNA vaccine preparations; medical preparations for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; medicinal preparations for the treatment of infectious diseases and for use in oncology; mixed biological preparations, namely, RNA and DNA therapeutics for the prevention and treatment of infectious diseases; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; pharmaceutical preparations for the treatment of viral diseases; pharmaceutical products, namely, RNA and DNA therapeutics for the treatment of joint disease; pharmaceutical products, namely, RNA and DNA therapeutics for the treatment of viral and infectious diseases, for the treatment of cancer; therapeutic vaccines, namely, RNA and DNA therapeutics; all of the foregoing excluding medicinal dietary and nutritional supplements |
| Pseudo Mark | RENAGADE RENEGADE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, May 26, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Renagade Therapeutics LLC |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Cambridge, MA 02142 |
| Party Name | Renagade Therapeutics LLC |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Cambridge, MA 02142 |
| Event Date | Event Description |
| Saturday, February 27, 2021 | NEW APPLICATION ENTERED |
| Wednesday, May 26, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, September 15, 2021 | ASSIGNED TO EXAMINER |
| Wednesday, September 15, 2021 | NON-FINAL ACTION WRITTEN |
| Wednesday, September 15, 2021 | NON-FINAL ACTION E-MAILED |
| Wednesday, September 15, 2021 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Sunday, December 26, 2021 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Sunday, December 26, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, December 27, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, January 26, 2022 | FINAL REFUSAL WRITTEN |
| Wednesday, January 26, 2022 | FINAL REFUSAL E-MAILED |
| Wednesday, January 26, 2022 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Tuesday, July 26, 2022 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Tuesday, July 26, 2022 | EXPARTE APPEAL RECEIVED AT TTAB |
| Tuesday, July 26, 2022 | JURISDICTION RESTORED TO EXAMINING ATTORNEY |
| Tuesday, July 26, 2022 | EX PARTE APPEAL-INSTITUTED |
| Saturday, August 20, 2022 | ASSIGNED TO LIE |
| Saturday, August 20, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Saturday, August 20, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, August 22, 2022 | ACTION CONTINUING FINAL - COMPLETED |
| Monday, August 22, 2022 | ACTION DENYING REQ FOR RECON E-MAILED |
| Monday, August 22, 2022 | NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED |
| Wednesday, January 4, 2023 | JURISDICTION RESTORED TO EXAMINING ATTORNEY |
| Wednesday, January 4, 2023 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Wednesday, January 4, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, January 4, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, February 7, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, February 22, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, March 14, 2023 | PUBLISHED FOR OPPOSITION |
| Tuesday, March 14, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Friday, March 17, 2023 | EXPARTE APPEAL TERMINATED |
| Tuesday, May 9, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Friday, October 20, 2023 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, October 24, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, February 20, 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Tuesday, February 20, 2024 | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Tuesday, February 20, 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Tuesday, February 20, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, April 9, 2024 | SOU EXTENSION 2 GRANTED |
| Tuesday, April 9, 2024 | SOU EXTENSION 2 FILED |
| Tuesday, April 9, 2024 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, April 10, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, October 20, 2023 | SOU EXTENSION 1 GRANTED |
| Friday, October 20, 2023 | SOU EXTENSION 1 FILED |